Expect Questions About Trelegy for Asthma

November 2020

The "three-in-one" Trelegy Ellipta inhaler is now approved for ASTHMA...not just for COPD.

Trelegy contains the inhaled corticosteroid (ICS) fluticasone furoate...the long-acting beta-agonist (LABA) vilanterol...and the long-acting muscarinic antagonist (LAMA) umeclidinium.

Trelegy seems to improve lung function in asthma patients not controlled on a medium- or high-dose ICS/LABA...but isn't yet shown to reduce exacerbations.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Practice Educate About Limitations of COVID-19 Antibody Testing
Fever Improve Accuracy of Noncontact Infrared Thermometers
Immunizations Use Immunization Registries to Optimize Vaccinations
Substance Use Disorder Stay Alert for Unexpected Culprits of Rx and OTC Med Misuse
Supplements Clear Up Confusion About "Memory Supplements"
Med Administration Know When to Give Patients a "Green Light" to Cut or Crush Meds
Asthma Expect Questions About Trelegy for Asthma
Multiple Sclerosis Be Familiar With the Latest Oral Multiple Sclerosis Meds
Depression Stay Alert for Depression During and After Pregnancy
Medicare Expect Changes for Medicare Part D in 2021
Infectious Diseases Answer Questions About Using Steroids for COVID-19
Practice Evaluate if Guidelines "Fit" Your Patients

Expect Questions About Trelegy for Asthma

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents